Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $11.13

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.13.

STRO has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a report on Monday, November 18th. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a report on Tuesday, December 10th. Wells Fargo & Company decreased their price objective on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Sutro Biopharma in a research report on Friday, October 11th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th.

Institutional Trading of Sutro Biopharma

Institutional investors have recently bought and sold shares of the business. Gladius Capital Management LP acquired a new position in Sutro Biopharma in the 3rd quarter valued at approximately $28,000. ProShare Advisors LLC raised its position in shares of Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after purchasing an additional 5,373 shares during the period. Virtu Financial LLC acquired a new position in Sutro Biopharma during the third quarter worth $77,000. Intech Investment Management LLC purchased a new stake in shares of Sutro Biopharma in the third quarter worth approximately $91,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Sutro Biopharma by 27.4% in the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after purchasing an additional 7,082 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $1.93 on Monday. Sutro Biopharma has a 1 year low of $1.70 and a 1 year high of $6.13. The business has a fifty day moving average of $2.98 and a 200-day moving average of $3.50. The stock has a market cap of $159.15 million, a price-to-earnings ratio of -1.20 and a beta of 1.09.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.